<DOC>
	<DOC>NCT00410514</DOC>
	<brief_summary>This study examined the safety, tolerability, and efficacy of mirabegron (YM178) compared to placebo.</brief_summary>
	<brief_title>A Study of Mirabegron (YM178) in Men With Lower Urinary Tract Symptoms (LUTS) and Bladder Outlet Obstruction (BOO)</brief_title>
	<detailed_description />
	<mesh_term>Lower Urinary Tract Symptoms</mesh_term>
	<mesh_term>Urinary Bladder Neck Obstruction</mesh_term>
	<mesh_term>Mirabegron</mesh_term>
	<criteria>Men 45 years of age or older Documented bladder outlet obstruction History of urinary retention Symptomatic and recurrent urinary tract infection (UTI)</criteria>
	<gender>Male</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>Beta-3 Receptor Agonist</keyword>
	<keyword>YM178</keyword>
	<keyword>Men</keyword>
	<keyword>Lower Urinary Tract Symptoms</keyword>
	<keyword>Bladder Outlet Obstruction</keyword>
</DOC>